Background and Purpose-Carotid artery revascularization was previously found to incrementally reduce stroke risk among patients with carotid stenosis treated with medical therapy. However, the frequency with which optimal medical therapies are used at discharge after carotid endarterectomy (CEA) and carotid artery stenting (CAS) is not known, and the influence of patient, operator, and hospital characteristics on the likelihood of prescription is poorly understood. Methods-In a retrospective cohort study of 23 112 patients undergoing CAS or CEA between January 2007 and June 2012 at US hospitals participating in the CARE registry (Carotid Artery Revascularization and Endarterectomy), we examined antiplatelet therapy and statin utilization at discharge. Hierarchical multivariable logistic regression was used in adjusted analyses. Results-Antiplatelet agents and statins were prescribed at discharge in 99% and 78%, respectively, after CAS and 93% and 75%, respectively, after CEA. After adjustment, antiplatelet therapy was more often prescribed after CAS than CEA (odds ratio 2.4 [95% confidence interval 1.68-3.45]), but statin prescription was equally likely (odds ratio 1.11 [95% confidence interval 0.84-1.49]). Operator specialty (medical>radiology/surgery) and hospital community setting (suburban>urban>rural) independently predicted antiplatelet and statin agent use at discharge, whereas hospital geographic location (Northeast>Midwest/South>West) predicted use of statins but not antiplatelet therapy at discharge. Conclusions-US antiplatelet agent and statin discharge prescription rates were suboptimal after both CAS and CEA and varied by revascularization modality, operating physician specialty, and hospital characteristics. Improved and more uniform utilization after these procedures will be critical to the success of comprehensive stroke risk reduction efforts.
A ntiplatelet agents and statins reduce the incidence of death, myocardial infarction, and stroke among those with established atherosclerotic vascular disease, including carotid artery stenosis. 1, 2 Carotid endarterectomy (CEA) plus medical therapy was previously shown to incrementally reduce stroke risk among patients with carotid stenosis when compared with medical therapy alone. 3 Although the long-term risk of periprocedural death or stroke is marginally higher after carotid artery stenting (CAS) than CEA, CAS has been proven equivalent to CEA for the composite end point, death, myocardial infarction, or stroke. 4 Whether evidence-based medical therapies are prescribed equally often among patients who undergo CAS and CEA has implications for overall atherothrombotic event (including stroke) risk reductions afforded by these respective revascularization modalities in the real world. Using data from the CARE registry (Carotid Artery Revascularization and Endarterectomy), we compared rates of antiplatelet agent and statin prescription at discharge among patients who underwent CAS or CEA and examined the independent influence of patient, operator, and hospital characteristics on respective prescription rates.
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Association of Neurological Surgeons/Congress of Neurological Surgeons. Adult patients, 18 years of age or older, who undergo CAS or CEA at participating US institutions are consecutively enrolled. Standard data definitions, collection protocols, and collection tools are used and are detailed at the National Cardiovascular Data Registry (NCDR) website: http://www.ncdr.com. Medications given preprocedure, intraprocedure, postprocedure, and at discharge are designated as administered, not administered, or contraindicated (contraindicated is not registry-defined but left to the discretion of the treating physician [eg, for patients with allergies/intolerances]). Trained personnel at each site abstract medication prescription data from clinical records.
Patients
Exclusion criteria and corresponding patient numbers are shown in Figure 1 .
Operators
National Provider Identifier numbers for CARE registry operators were merged with healthcare provider data from the National Plan and Provider Enumeration System (NPPES; http://nppes.viva-it. com/NPI_Files.html). NPPES data include Healthcare Provider Taxonomy Codes, which categorize providers by type, classification, and specialization and were used to determine operator specialty as defined in the Washington Publishing Company Healthcare Provider Taxonomy Code Set (http://www.wpc-edi.com/reference/). Taxonomy codes were merged as detailed in Methods in the onlineonly Data Supplement . In the analysis by operator (Figure 1 ), procedures were excluded if operator specialty could not be determined (n=2079) or if an invalid operator specialty was listed (ie, medical or radiology specialty listed for CEA; n=61.
Hospitals
Hospitals were grouped according to US Census Bureau region (West, Northeast, South, and Midwest) and by community setting (suburban, urban, or rural) . Institutions self-designate as teaching versus nonteaching.
Outcomes
The primary study outcomes were antiplatelet agent (aspirin, thienopyridine, or the combination) and statin prescription at discharge.
Secondary outcomes included prescription of aspirin and thienopyridine monotherapy and dual antiplatelet therapy (DAPT; aspirin plus thienopyridine) preprocedure and at discharge; new antiplatelet and DAPT starting at discharge among those who were not on these preprocedure; and any cholesterol-lowering agent (statin or nonstatin) use at discharge. Patients taking/prescribed combination aspirindipyridamole would have been considered in the aspirin group and analyzed accordingly. Preprocedure cholesterol-lowering therapy was not recorded.
Statistical Analysis
Categorical variables are presented as frequencies and percentages, and unadjusted comparisons were made using χ 2 or Fisher exact tests where appropriate. Continuous variables are presented as mean±standard deviation (median with interquartile range where non-normally distributed), and unadjusted comparisons were made using t tests or Mann-Whitney tests where appropriate. Separate models were generated for antiplatelet agent and statin prescription at discharge using hierarchical multivariable logistic regression (see Methods in the online-only Data Supplement for model covariates). We used hospital site as a random effect in these models to account for patient clustering in sites. Statistical significance was defined as P<0.05. All statistical analyses were performed using SAS Version 9.2 (SAS Institute, Cary, NC).
Results
Patients/Procedures
There were 25 442 procedures entered into the CARE registry between January 1, 2007, and June 30, 2012 . After exclusions, the analytic cohort comprised 23 112 procedures, 12 628 CAS, and 10 484 CEA. Patient and procedural characteristics for the overall cohort and separately for those undergoing CAS and CEA are given in Table 1 .
Revascularization Modality
Mean age and sex were similar across modalities, but those who underwent CAS had a significantly greater prevalence of comorbidities, including hypertension, dyslipidemia, diabetes mellitus, chronic kidney disease, coronary artery disease, peripheral arterial disease, heart failure, history of permanent pacemaker or defibrillator, and chronic lung disease. Patients who underwent CAS were also more likely to have unfavorable anatomic features, including prior neck radiation, prior neck surgery, contralateral carotid artery occlusion, previous CAS or CEA, and CAS or CEA restenosis. Finally, those who underwent CAS had worse cardiac and neurological symptom status; they were more likely than those undergoing CEA to have Canadian Cardiovascular Society Class III or IV angina, to haveNew York Heart Association Class III or IV heart failure, or to have had antecedent neurological symptoms (including during the prior 6 months).
Unadjusted preprocedure and discharge medical therapy use according to revascularization modality are provided in Table 2 . Pretreatment with antiplatelet therapy, aspirin, a thienopyridine, or DAPT was significantly more common before CAS than CEA. Antiplatelet agents (99% versus 93%; P<0.001), aspirin, a thienopyridine, and DAPT were given significantly more often at discharge after CAS than CEA as well. New antiplatelet agent starts were more likely among CAS than CEA patients, as were new thienopyridine and new DAPT starts. Of the 870 patients who underwent either CAS or CEA and who were not on an antiplatelet agent at discharge, 245 (28.1%) were on warfarin. Statins were also prescribed more commonly at discharge after CAS than CEA (78% versus 75%; P<0.001). The likelihood of discharge on optimal medical therapy (ie, both an antiplatelet and statin agent) was significantly greater after CAS than CEA.
Operators
Of 11 Unadjusted preprocedure and discharge medical therapy prescription rates for CAS varied according to operator specialty and is detailed in Table I in the online-only Data Supplement. Antiplatelet therapy was prescribed at discharge by medical specialists, radiologists, and surgeons in 99%, 98%, and 97%, respectively (P<0.001). Discharge statin prescription rates for these specialties were 81%, 69%, and 70%, respectively (P<0.001). Prescription rates before and at discharge after CEA also varied by operator subspecialty and is detailed in Table  II in the online-only Data Supplement. Discharge antiplatelet agent use varied significantly across surgical subspecialty, 
Hospitals
Unadjusted prescription rates for medical therapies before and at discharge after carotid artery revascularization stratified by geographic region are provided in Table III 
Independent Predictors of Medical Therapy Prescription at Discharge
When patient, operator, and hospital characteristics were entered into a model predicting antiplatelet agent utilization at discharge (Figure 2 ), carotid revascularization modality, operator specialty, and hospital community setting remained significant independent predictors: CAS>CEA; medical>radiology, medical>surgery, general<thoracic surgery, general<vascular surgery, thoracic<vascular surgery; rural<suburban, rural<urban, and suburban>urban. When operator and hospital characteristics were included in a model predicting statin prescription at discharge (Figure 3 ), carotid revascularization modality was no longer an independent predictor. However, operator specialty, hospital geographic region, and hospital community setting remained significant, independent predictors of statin use: medical>radiology, medical>surgery, general<neurosurgery, neuro>thoracic surgery, and neuro>vascular surgery; West< Northeast, West<Midwest, West<South, Northeast>Midwest, Northeast>South; rural<suburban, rural<urban and, suburban> urban.
Discussion
There have been few real-world studies examining periprocedural antiplatelet and cholesterol-lowering agent use after CEA 5 and even fewer after CAS 6 ; comparisons of antiplatelet and statin utilization rates across revascularization strategies have also been uncommon, and the largest studies to date have been regional in nature. 6 Using a large, multicenter US registry, we identified significant underutilization and variation in the use of evidence-based medical therapy at hospital discharge after carotid artery revascularization. Although only 4% of eligible patients were discharged without an antiplatelet agent, 1 in 4 went home without a statin.
Several factors, including carotid artery revascularization modality, operator specialty, and hospital characteristics, significantly and independently predicted the use of medical therapy at discharge, and although significant differences are often present when comparing groups in large data sets, we think that these relationships are clinically meaningful. The likelihood of receiving an antiplatelet agent at discharge was higher after CAS than after CEA, whereas statins were similarly prescribed after either revascularization modality. The probability of receiving an antiplatelet agent or a statin at discharge was highest for medical specialists, intermediate for radiologists, and lowest when the procedure was performed by a surgeon; among surgical subspecialties, vascular surgeons were more likely than thoracic surgeons who were in turn more likely than general surgeons to prescribe antiplatelet therapy at discharge. Neurosurgeons were more likely to prescribe a statin at discharge than general, thoracic, or vascular surgeons. We also found that the likelihood of receiving antiplatelet therapy or a statin at discharge was highest in suburban, intermediate in urban, and lowest in rural community hospital settings, and that statins were most commonly prescribed at discharge at hospitals in the Northeast and least commonly in the West. Underutilization and variation in use of aspirin and statin therapy at discharge were observed among patients undergoing elective vascular surgical procedures within the Vascular Study Group of New England. 6 Ours is the first national registry analysis to specifically examine utilization of antiplatelet therapy and statins at discharge after CEA and CAS.
Identifying, explaining, and correcting unnecessary variation in antiplatelet therapy and statin utilization at discharge after CAS and CEA is of critical importance because both reduce the relative risk of first or recurrent stroke in patients with carotid artery stenosis by ≈25%.
1,2 Multispecialty guidelines provide a Class I recommendation for their use in this patient population, 7 and utilization of these agents is included among consensus PAD performance measures. 8 Although carotid artery revascularization procedures also reduce stroke risk [9] [10] [11] and multispecialty guidelines suggest that both CAS and CEA are indicated for this purpose, 12 it would be difficult to justify performance of CAS or CEA, given their inherent risk of procedural complications, without simultaneously using comprehensive stroke risk reduction interventions that include effective and relatively safer medical therapies.
Whether medical therapy is optimally prescribed after carotid artery revascularization in the real world is also germane to the ongoing CREST-2 (Carotid Revascularization Endarterectomy versus Stent Trial 2), which is comparing long-term stroke risk among asymptomatic patients with carotid artery stenosis treated with revascularization plus optimal medical therapy versus optimal medical therapy alone. CREST-2 results will only be generalizable if medical therapy is optimally prescribed in real-world practice.
Patient, physician, pharmacy, and prescription characteristics may influence statin adherence in the outpatient setting, 13 but less is known about factors that influence prescription of medical therapy at the time of discharge. Other studies have identified lower rates of evidence-based prescribing during hospitalization in more remote areas 14 and have identified physician specialty and hospital geographic region as independent predictors of evidence-based medical therapy prescription at discharge. 15 In our study, hospital and physician characteristics were important predictors of antiplatelet agent and statin use at discharge.
National quality improvement initiatives have successfully increased prescription of evidence-based medical therapies at discharge among patients with established atherosclerotic vascular disease through registry participation. 16 We observed that statin therapy use at discharge increased with the length of time a center participated in the CARE registry (data not shown). It is plausible that distribution of quarterly registry reports to operators and institutions resulted in improved discharge statin prescription over time.
Limitations
Although CARE contains records from a large cohort of patients, it represents a subset of all who underwent CAS or CEA in the United States during the study period; consequently, our findings may not be applicable to all such patients. Although patients with contraindications to these agents were excluded from our study by design, failure to record medication allergies or intolerances may have led us to underestimate discharge medication utilization rates. Cross-specialty differences in capturing accurate clinical data 17 may have also led to underestimates in use rates for some groups. In contrast, as participation in CARE was voluntary, enrolling hospitals and providers may have inherently possessed a greater commitment to quality improvement than those who did not participate, which may have led to an overestimation of real-world antiplatelet therapy and statin use rates. Real-world medical therapy use rates for patients with carotid stenosis who do not undergo carotid revascularization may be even lower; studies of patients with coronary disease suggest that statin prescription rates at discharge are higher among those who are revascularized than among those who are treated with medical therapy alone. 18 Because medication use was not measured after hospital discharge, it is not possible to ascertain long-term utilization rates for these agents or whether optimization (ie, statin dose escalation) occurred. Although it remains possible that patients discharged without antiplatelet therapy or a statin ultimately began taking these agents in the outpatient setting (the CARE registry does not ascertain medication utilization after hospital discharge, nor does it capture whether a physician recommended but did not prescribe a particular agent), this supposition has not borne out in clinical trials 19 or in registries 20 ; patients seem much more likely to use evidence-based medical therapies if they continue them from discharge than if they are left to initiate them in the outpatient setting.
Finally, because most patients remain hospitalized at least overnight after carotid revascularization procedures, it remains possible that physicians from specialties other than those who performed the CAS or CEA were responsible for prescribing medications at discharge. Such handoffs may be more likely among patients who undergo carotid artery revascularization at the hands of nonmedical specialists. Nevertheless, if this were to have occurred, it should have made identification of cross-specialty differences less rather than more likely.
Summary/Conclusions
In this national, multicenter registry of patients undergoing CAS or CEA, we identified suboptimal rates of antiplatelet therapy and statin prescription at discharge among those without reported contraindications. Use rates varied by revascularization modality, operating physician specialty, and hospital characteristics. There remain tremendous opportunities to improve and reduce variability in utilization of evidence-based medical therapy in this setting.
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Discharge antiplatelet agent and statin model covariates
Separate models were generated for antiplatelet agent and statin prescription at discharge by incorporating procedure date, physician specialty, hospital characteristics, and other patient features, including age, gender, estimated glomerular filtration rate, history of hypertension, dyslipidemia, diabetes mellitus, smoking, ischemic heart disease, angina, myocardial infarction, heart failure, New York Heart Association heart failure class, peripheral arterial disease, atrial fibrillation, cardiac pacemaker, cardiac valve disease including aortic stenosis, mitral stenosis or a previous mechanical valve, dialysis, chronic lung disease, ischemic stroke, transient ischemic attack, hemorrhagic stroke, dementia, seizure, prior CAS, prior CEA, symptomatic target carotid artery lesion, CAS restenosis, CEA restenosis, contralateral carotid artery occlusion, prior neck radiation therapy, prior neck surgery, tracheostomy in place, or awaiting major surgery. 
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